Latest news
Latest news
Meet 3 leaders who are breaking new ground for women in healthcare
For International Women’s Day, celebrate the achievements of these amazing female scientists and researchers at Johnson & Johnson.
What to know about low vision
Low vision isn’t the same as blindness, but navigating daily life with it is still challenging. For Low Vision Awareness Month, learn the facts—plus, the promising treatment innovations that are in the works.
More from Johnson & Johnson
What is an orphan drug?
The need for these rare disease therapies is strong, and access to them can be lifesaving. Here’s how Johnson & Johnson is innovating to help give patients options.
Heart failure is probably not what you think it is
For American Heart Month, learn about the advances Johnson & Johnson is making to help turn heart failure into heart recovery for the millions of adults in the U.S. living with the condition, which occurs when the heart muscle isn’t able to pump blood as well as it should.
3 health advocates; 1 Johnson & Johnson program that offers empowerment and connection
In the quest to solve the toughest health challenges, innovating therapies and finding treatments are essential—but so is supporting the patients living with these diseases. That’s exactly why Johnson & Johnson launched HealtheVoices a decade ago.
What is cardiac ablation?
For American Heart Month, learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.
Johnson & Johnson named a 2024 Fortune World’s Most Admired Company
The company makes the list for the 22nd year in a row, thanks to its dedication to innovation, social responsibility and more.
Could we be on the cusp of catching Alzheimer’s before it starts?
The key to slowing cognitive decline is diagnosing the disease as early as possible. And that’s exactly what Johnson & Johnson scientists are relentlessly pursuing.
Press releases
Johnson & Johnson MedTech working with NVIDIA to scale AI for surgery
Johnson & Johnson MedTech is working with NVIDIA on how its technologies can accelerate secure, real-time analysis of surgical data at the edge Johnson & Johnson MedTech will enable AI-based model development and application deployment, providing a path to scale within its connected digital ecosystem for surgery
RYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson’s ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer
Featured data include new results from the Phase 3 MARIPOSA study, which has received U.S. FDA Priority Review, and the Phase 1b PALOMA study of subcutaneous amivantamab
U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI® (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma
FDA ODAC unanimously votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI® based on results from the Phase 3 CARTITUDE-4 study
Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA®(guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis
Submission is supported by data from the Phase 3 QUASAR program, which showed a significantly greater percentage of patients with moderately to severely active ulcerative colitis who received TREMFYA® achieved clinical remission at Week 44 compared with placebo
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
JNJ-2113 long-term extension FRONTIER 2 study demonstrated sustained efficacy from Week 16 to Week 52 and safety results consistent with previously reported data (FRONTIER 1 Study) in a late-breaking oral presentation at the American Academy of Dermatology 2024 Annual Meeting